Detection and localization of surgically resectable cancers with a multi-analyte blood test
- Author(s)
- Cohen, JD; Li, L; Wang, Y; Thoburn, C; Afsari, B; Danilova, L; Douville, C; Javed, AA; Wong, F; Mattox, A; Hruban, RH; Wolfgang, CL; Goggins, MG; Dal Molin, M; Wang, TL; Roden, R; Klein, AP; Ptak, J; Dobbyn, L; Schaefer, J; Silliman, N; Popoli, M; Vogelstein, JT; Browne, JD; Schoen, RE; Brand, RE; Tie, J; Gibbs, P; Wong, HL; Mansfield, AS; Jen, J; Hanash, SM; Falconi, M; Allen, PJ; Zhou, S; Bettegowda, C; Diaz, L; Tomasetti, C; Kinzler, KW; Vogelstein, B; Lennon, AM; Papadopoulos, N;
- Details
- Publication Year 2018-01-18,Volume 359,Issue #6378,Page 926-930
- Journal Title
- Science
- Publication Type
- Journal Article
- Abstract
- Earlier detection is key to reducing cancer deaths. Here we describe a blood test that can detect eight common cancer types through assessment of the levels of circulating proteins and mutations in cell-free DNA. We applied this test, called CancerSEEK, to 1,005 patients with non-metastatic, clinically detected cancers of the ovary, liver, stomach, pancreas, esophagus, colorectum, lung, or breast. CancerSEEK tests were positive in a median of 70% of the eight cancer types. The sensitivities ranged from 69% to 98% for the detection of five cancer types (ovary, liver, stomach, pancreas, and esophagus) for which there are no screening tests available for average-risk individuals. The specificity of CancerSEEK was > 99%: only 7 of 812 healthy controls scored positive. In addition, CancerSEEK localized the cancer to a small number of anatomic sites in a median of 83% of the patients.
- Publisher
- AAAS
- Research Division(s)
- Systems Biology And Personalised Medicine
- PubMed ID
- 29348365
- Publisher's Version
- https://doi.org/10.1126/science.aar3247
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2018-02-27 12:34:59
Last Modified: 2018-02-27 01:01:51